Effects of competitive platelet glycoprotein IIb/IIIa inhibition with velofibatide (integrilin) in reducing complications of percutaneous coronary intervention: results of the randomized clinical trial IMPACT-II - IMPACT-II Investigators. (Lancet, 1997)